The Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University spoke on the safety and efficacy of ublituximab in treating patients with relapsing forms of multiple sclerosis. [WATCH TIME: 4 minutes]
WATCH TIME: 4 minutes
“The antibody, ublitixumab, is glycoengineered, the sugars have been engineered so that the infusion time can be reduced. Essentially, after the first infusion, individuals come in every 6 months, and it's a 1-hour process. Assuming the parking is good where you come in to get your infusion, you can get back to school or get back to work or get back to your life [in a timely manner], and I think this will be a very attractive advantage compared to other infusion-based therapies for multiple sclerosis.”
Data from the identical phase 3 ULTIMATE 1 and 2 trials (NCT03277261; NCT03277248) were presented at the 37th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), October 13-15, outlining the safety and efficacy of a 1-hour infusion of ublituximab (TG Therapeutics) every 6 months, with an initial infusion of 150mg over a 4-hour period, in patients with relapsing multiple sclerosis. Lawrence Steinman, MD, Zimmermann Professor of Neurology and Neurological Sciences, and Pediatrics at Stanford University, sat down with NeurologyLive to discuss findings from both trials, which met their primary end point in significantly reducing annualized relapse rate (ARR) and MRI parameters over a 96-week period, compared to teriflunomide (Aubagio; Sanofi).
Steinman, the principal investigator for both trials, outlined data on ublituximab, an investigational glycoengineered anti-CD20 monoclonal antibody, and commented on the results, which were “virtually identical” to the previous phase 2 trials. The time-effective nature of the treatment is another appealing aspect, Steinman said, as the process takes 1 hour every 6 months, and with ublituximab having been glycoegineered, infusion time is reduced.
For more coverage of ECTRIMS 2021, click here.